Cosmetic Pre-Assessment: The Strategic Step That Saves Time and Money
Before any marketing, it is essential to demonstrate that the product is safe for human health. This demonstration is based on the Cosmetic Safety Report (RSPC).
But even before writing this report, a step is too often overlooked and yet essential: the cosmetic pre-assessment of the formula (toxicological and regulatory).
As an expert in cosmetic regulations, Toxi Plan explains everything you need to know about cosmetic pre-assessment. 
1. Why start with a cosmetic pre-assessment
before conducting a safety evaluation?
When a company develops a cosmetic product, priority is often given to the formulation, product efficacy or sensory experience. Yet, before any marketing, one element is absolutely essential: demonstrate that the product is safe for human health. This demonstration is based on a mandatory document in the European Union: the Cosmetic Product Safety Report (RSPC).
But even before writing this report, one step needs to be highlighted: the toxicological and regulatory pre-evaluation of the formula. At Toxi Plan, we consider this step as a real lever for optimizing product development. Carried out sufficiently early in the project, pre-evaluation allows both to secure the regulatory compliance of the formula and to define the most relevant testing strategy.
Result: fewer regulatory risks, fewer unnecessary tests, and often several weeks saved in the development schedule.
2. Why start with a cosmetic pre-assessment before conducting a safety evaluation?
European cosmetic regulations require that every cosmetic product undergo a safety evaluation performed by a qualified toxicologist. To conduct this evaluation, a significant amount of information must be available, including the exact composition of the formula, toxicological data for the ingredients, product characteristics, and certain tests demonstrating product quality and tolerance. In practice, many companies begin by launching tests or preparing regulatory documentation without first analyzing the formula and the available data.
This approach can lead to several issues:
- non-compliant ingredients discovered too late
- missing supplier documentation
- unnecessary testing
- delays in bringing the product to market.
A pre-assessment helps avoid these situations. It acts as a regulatory and toxicological diagnostic of the product, allowing teams to secure the project before investing in additional testing or regulatory steps.
Each product must be distinguished to carry out a cosmetic pre-evaluation for each one.
3. Cosmetic pre-assessment: a key step in the
cosmetic safety evaluation process
Several steps in the regulatory evaluation of a cosmetic product
The first step is the regulatory and toxicological pre-assessment, which analyzes the formula and the available documentation.
This analysis allows us to:
- verify the compliance of the formula
- identify missing technical documentation
- determine which tests are truly necessary based on the product’s intended use and claims.
Once this analysis is completed, the second step can start : missing information can be obtained from suppliers and the necessary tests can be launched.
The third step is the preparation of the Cosmetic Product Safety Report (CPSR) by a toxicologist. This report confirms that the product is safe for human health under normal conditions of use.
Finally, the last and fourth step : CPSR is included in the Product Information File (PIF), which must be maintained by the responsible person and made available to authorities if required. The product must also be notified on the European CPNP portal before beingplaced on the market.
Within this process, the pre-assessment plays a critical role because it helps secure all the steps that follow.
4. Verifying the regulatory compliance of the formula
1st mission of the pre-evaluation
The first objective of the pre-assessment is to ensure that the formula complies with European cosmetic regulations. Each ingredient is analyzed to verify that it meets applicable regulatory requirements. This analysis helps identify the possible presence of prohibited substances, restricted ingredients, or substances classified as CMR (carcinogenic, mutagenic, or toxic for reproduction).
CMR substances are subject to strict scrutiny under cosmetic regulations. Their presence in a formula may require detailed analysis or may prevent the product from being marketed altogether. The pre-assessment also includes a review of the technical documentation provided by raw material suppliers. Technical data sheets and toxicological data are examined to identify any potential toxicological alerts associated with the ingredients.
Identification of upstream problems
This step makes it possible to detect regulatory issues at the earliest stage of the project. In some cases, the pre-assessment reveals a regulatory non-compliance that prevents the project from moving forward.
Example : during the analysis of a formula, a raw material used in the composition of the product was found to be listed in Annex II of the European Cosmetic Regulation, which contains substances prohibited in cosmetic products.
In this situation, the formula must be modified before the project can proceed.
In another case, the analysis of the perfume used in a formula revealed the presence of substances classified as CMR. This situation also requires a revision of the formula before any further development.
Identifying these problems at this stage helps to avoid launching costly tests on a formula that could not be marketed. It is a step of the JN Method (Just Necessary), a strategic approach aimed at defining the level of regulatory evidence strictly required to demonstrate safety and biocompatibility.
5. Defining a relevant testing strategy
2nd goal of the pre-evaluation
The second objective of the pre-assessment is to define the most appropriate testing strategy for the product.
Several types of tests may be conducted during the development of a cosmetic product to document its safety and quality. Some tests are generally necessary to demonstrate product stability and microbiological safety.
For example, stability studies, packaging compatibility tests, and challenge tests are commonly required to ensure that the preservative system is effective and that the product remains stable over time.
However, other tests may or may not be required depending on the specific characteristics of the formula.
The pre-assessment analyzes the ingredients and the available toxicological data to determine which tests are truly necessary.
This analysis can determine, for example, whether a patch test is required to demonstrate skin tolerance or whether existing toxicological data are sufficient to support the safety evaluation.
It also helps evaluate the relevance of ocular irritation tests for products intended for use around the eyes.
6. The cosmetic pre-assessment at Toxi Plan
A relevant and reliable support
At Toxi Plan, the pre-assessment represents the first step in our regulatory support for cosmetic projects.
To perform this analysis, we need access to the complete formula of the product along with key technical information about the raw materials.
We review several types of documentation, including:
- Safety Data Sheets or technical data sheets
- full INCI composition
- impurity data
- declarations related to nanoparticles when applicable
- information about the primary packaging.
This analysis allows us to verify the regulatory compliance of the formula, identify potential toxicological alerts, and define the most appropriate testing strategy.
For product development teams, this step provides valuable guidance for decision-making.
It helps secure the formula before additional costs are incurred and optimizes the overall project timeline.
FAQ - Your regular questions
One of the most tangible benefits of a pre-assessment is the optimization of testing. Without a preliminary analysis, some companies choose to perform multiple tests as a precaution in order to secure their regulatory documentation. This approach can generate unnecessary costs and extend development timelines.
A pre-assessment allows for a more targeted and scientifically grounded approach.
Example: in a recent project, the analysis of the formula and the available toxicological data showed that the existing information was sufficient to support the safety evaluation. The patch test initially considered was therefore not necessary.
As a result, the company saved approximately €500 and avoided adding several weeks to the product development timeline.
In many projects, this step helps identify which tests are truly required and which ones can be avoided without compromising the robustness of the safety evaluation.
At Toxi Plan, a pre-assessment represents a relatively small investment compared with the overall cost of developing a cosmetic product.
The price generally ranges between €300 and €600 per product, depending on the complexity of the formula.
Considering the potential savings from avoiding unnecessary tests and the time gained during development, this step often proves to be a highly cost-effective investment.
Ideally, a pre-assessment should be conducted once the formula is stabilized, before launching tests or initiating regulatory documentation. The earlier this analysis is performed, the more it can help optimize product development.
It allows companies to:
- avoid launching tests on a non-compliant formula
- anticipate missing documentation from suppliers
- structure the regulatory process more efficiently.
A pre-assessment is often the step that transforms a cosmetic concept into a robust regulatory file. It allows companies to quickly identify regulatory risks, define the most appropriate testing strategy, and optimize both costs and development timelines.
If you are developing a cosmetic product and want to verify the compliance of your formula or define the most appropriate testing strategy, Toxi Plan can support you starting from the pre-assessment stage.
A preliminary analysis can save valuable time and prevent unnecessary expenses in your project.
Disclaimer:
The information provided in this article is for informational and educational purposes only. It does not constitute legal advice nor a personalized regulatory consultation. Despite the care taken in drafting this article and verifying its sources, regulations evolve regularly and may be subject to differing interpretations depending on the specific context of each company, product, or market.
Toxi Plan®, its directors, and its employees shall not be held liable for any use made of the information contained in this article without further analysis tailored to a specific situation. Any regulatory or strategic decision should be based on a specific assessment carried out by a qualified professional, with due regard to the applicable regulations, including any provisions or regulatory practices entering into force after the date of publication.